

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM605590

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Akorn, Inc.		10/01/2020	Corporation: LOUISIANA
Advanced Vision Research, LLC		10/01/2020	Limited Liability Company: DELAWARE
Hi-Tech Pharmacal Co., LLC		10/01/2020	Limited Liability Company: DELAWARE
Akorn Animal Health, LLC		10/01/2020	Limited Liability Company: DELAWARE
Clover Pharmaceuticals LLC		10/01/2020	Limited Liability Company: DELAWARE
Akorn International S.À.R.L.		10/01/2020	Private Limited Liability Company: LUXEMBOURG
Oak Pharmaceuticals, LLC		10/01/2020	Limited Liability Company: DELAWARE
Inspire Pharmaceuticals, LLC		10/02/2020	Limited Liability Company: DELAWARE
Versa Pharm LLC		10/01/2020	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	Akorn Operating Company LLC
Street Address:	1925 W. Field Court
City:	Lake Forest
State/Country:	ILLINOIS
Postal Code:	60045
Entity Type:	Limited Liability Company: DELAWARE

PROPERTY NUMBERS Total: 58

Property Type	Number	Word Mark
Serial Number:	85114820	ADVANCING THE NEW VISION
Serial Number:	73652686	AK-FLUOR
Serial Number:	77589830	AKORN
Serial Number:	86937435	AKORN
Serial Number:	77012922	AKTEN
Serial Number:	75829828	AKWA TEARS
Serial Number:	72124870	AMICAR

TRADEMARK

Property Type	Number	Word Mark
Serial Number:	73815445	ANASED
Serial Number:	74628335	BETIMOL
Serial Number:	77492827	BUTORPHIC
Serial Number:	72221381	CAPASTAT
Serial Number:	85961915	CONTROL THE UNCONTROLLABLE
Serial Number:	74389373	DIABETIC TUSSIN
Serial Number:	86025876	DIADERM
Serial Number:	86773391	EYE RX DIRECT
Serial Number:	87007235	FAST AND FIERCE RELIEF
Serial Number:	72203731	FLURESS
Serial Number:	73652684	GENTAK
Serial Number:	85961910	GROUNDING IN SCIENCE. PROVEN IN PRACTICE
Serial Number:	75315149	IC-GREEN
Serial Number:	72190096	INAPSINE
Serial Number:	75825569	INDIGO CARMINE
Serial Number:	76308782	INSPIRE
Serial Number:	76309035	INSPIRE
Serial Number:	85121025	JEFFREY P. GILBARD, MD
Serial Number:	76052135	MAGINEX
Serial Number:	75576028	MAG-OX 400
Serial Number:	87007233	MASTER OF MAGNESIUM
Serial Number:	86210334	MULTI-BETIC
Serial Number:	76178246	MYOCHRYSSINE
Serial Number:	85071559	MYORISAN
Serial Number:	71308321	NEMBUTAL
Serial Number:	85967253	OSMO-CORRECTION
Serial Number:	75839701	PAREMYD
Serial Number:	78329276	PHARMACEUTICAL GRADE
Serial Number:	85967251	RESTORES EYES NATURAL BALANCE
Serial Number:	78862364	SINUS BUSTER
Serial Number:	78850704	SINUS BUSTER ALL NATURAL NASAL SPRAY
Serial Number:	78459733	STERILID
Serial Number:	75572570	T TAYLOR PHARMACEUTICALS AN AKORN COMPAN
Serial Number:	75829829	TEARS RENEWED
Serial Number:	88457133	THERA TEARS
Serial Number:	74615598	THERATEARS
Serial Number:	86260607	THERAPY FOR YOUR EYES
Serial Number:	87049747	THERATEARS EXTRA

Property Type	Number	Word Mark
Serial Number:	76427523	THERATEARS
Serial Number:	78459728	THERATEARS STERILID
Serial Number:	76548343	TOLAZINE
Serial Number:	86631044	TYPE YOU
Serial Number:	86966811	TYPE YOU DIABETIC CARE
Serial Number:	72450878	URO-MAG
Serial Number:	76269614	VERSAPHARM INCORPORATED
Serial Number:	76269637	VERSAPHARM INCORPORATED X
Serial Number:	74266573	VETAKET
Serial Number:	72081126	VO SOL
Serial Number:	73815446	YOBINE
Serial Number:	78660833	ZOSTRIX
Serial Number:	73576274	ZOSTRIX

CORRESPONDENCE DATA

Fax Number: 3128622200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3128622000

Email: rob.soneson@kirkland.com

Correspondent Name: Rob Soneson

Address Line 1: 300 N LaSalle

Address Line 2: Kirkland & Ellis LLP

Address Line 4: Chicago, ILLINOIS 60654

ATTORNEY DOCKET NUMBER:	14581-66-RFS
NAME OF SUBMITTER:	Rob Soneson
SIGNATURE:	/rsoneson/
DATE SIGNED:	10/28/2020

Total Attachments: 14

- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page1.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page2.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page3.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page4.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page5.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page6.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page7.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page8.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page9.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page10.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page11.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page12.tif

TRADEMARK ASSIGNMENT AGREEMENT

This TRADEMARK ASSIGNMENT AGREEMENT is dated as of October 1, 2020 (this “**Assignment**”), and is by and between Akorn, Inc., Advanced Vision Research, LLC, Hi-Tech Pharmacal Co., LLC, Akorn Animal Health, LLC, Clover Pharmaceuticals LLC, Akorn International S.À.R.L., Oak Pharmaceuticals, LLC., Inspire Pharmaceuticals, LLC, and VersaPharm LLC (each, an “**Assignor**” and collectively, the “**Assignors**”) on the one hand, and Akorn Operating Company LLC (“**Assignee**”) on the other hand. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Purchase Agreement (as defined below).

WHEREAS, Assignors are the owners of the trademark registrations and applications for which it is listed as the current owner of record on **Exhibit A** (collectively, the “**Assigned Trademarks**”);

WHEREAS, Assignors and Akorn Holdings Topco LLC (“**APA Purchaser**”) are parties to that certain Asset Purchase Agreement, dated as of May 20, 2020 (the “**Purchase Agreement**”), pursuant to which Purchaser agreed to purchase the Acquired Assets and agreed to assume the Assumed Liabilities from Sellers;

WHEREAS Assignors, Assignee, APA Purchaser, and certain other parties set forth on the signature pages thereto entered into that certain Implementation Agreement, dated as of the date hereof (the “**Implementation Agreement**”), providing for, among other things, (i) a G Reorganization Election and (ii) in order to implement the G Reorganization, an agreement among the parties thereto that, notwithstanding the provisions of the Purchase Agreement, on the date hereof (a) the Sellers will transfer, assign, convey, and deliver to Assignee all of the Sellers’ right, title and interest in the Acquired Assets, free and clear of all Encumbrances other than Permitted Encumbrances and (b) Assignee will assume from Sellers the Assumed Liabilities;

WHEREAS, in order to effectuate the transactions contemplated by the Purchase Agreement, as amended by the Implementation Agreement, and pursuant to the terms and conditions thereof, Assignors and Assignee are hereby effecting the sale, conveyance, assignment, and transfer of all of the Acquired Assets, which assets include the Assigned Trademarks; and

WHEREAS, this Assignment is being executed and delivered pursuant to Section 2.3(c) of the Purchase Agreement.

NOW, THEREFORE, in accordance with the Purchase Agreement, as amended by the Implementation Agreement, and in consideration of the premises and the mutual agreements and covenants set forth in this Assignment, the Purchase Agreement and the Implementation Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the parties hereby agree as follows:

1. Assignment. Each of the Assignors, subject to any encumbrances related to prior agreements, hereby irrevocably sells, conveys, transfers, assigns, and delivers to Assignee all of each Assignor’s worldwide right, title, and interest throughout the world in and to the Assigned Trademarks, together with that portion of such Assignor’s business connected with the use of and

symbolized by the Assigned Trademarks, and all past and present goodwill associated therewith or symbolized thereby, all common law rights thereto, all registrations that have been or may be granted thereon, all applications for registrations thereof, the right to claim priority in accordance with international treaties and conventions, the right to all income, royalties, damages, and payments hereafter due or payable with respect to the Assigned Trademarks, the right to register, prosecute, maintain, and defend the Assigned Trademarks before any public or private agency, office, or registrar, and all claims, causes of action, and rights to sue for past, present, and future infringement or unconsented use of the Assigned Trademarks. Each of the Assignors authorizes the Commissioner of Patents and Trademarks in the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign countries or multinational authorities, to record Assignee as the assignee of all of each Assignor's right, title, and interest in and to the Assigned Trademarks and to deliver to Assignee, and to Assignee's attorneys, agents, successors, or assigns, all official documents and communications.

2. Further Assurances. Assignor covenants and agrees that, at any time and from time to time upon the request of Assignee, Assignor shall provide any further necessary documentation and do all further acts reasonably requested by Assignee to confirm and perfect title in and to the Assigned Trademarks in Assignee, its successors, and assigns, at Assignee's sole cost and expense. If the Assignee is unable, after reasonable effort, to secure the Assignor's signature on any such documentation for any reason whatsoever, Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as such Assignor's agent and attorney-in-fact, to act for and in such Assignor's behalf and stead to execute and file any such documents and to do all other lawfully permitted acts to further the prosecution, issuance, and perfection of the Assigned Trademarks with the same legal force and effect as if executed by such Assignor. For the avoidance of doubt, all fees incurred in connection with any filings relating to the assignment of the Assigned Trademarks with the United States Patent and Trademark Office or any foreign equivalent thereof will be paid by Assignee.

3. No Third Party Beneficiaries. This Assignment is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein expressed or implied shall give or be construed to give to any person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder.

4. Terms of Purchase Agreement; Conflicts. The scope, nature, and extent of the Acquired Assets are expressly set forth in the Purchase Agreement. Nothing contained herein changes, amends, modifies, extends, limits, or otherwise alters (nor shall this Assignment be deemed or construed as changing, amending, modifying, extending, limiting or altering) the terms or conditions of the Purchase Agreement, as amended by the Implementation Agreement, in any manner whatsoever. This instrument does not create or establish rights, liabilities, or obligations not otherwise created or existing under or pursuant to the Purchase Agreement, as amended by the Implementation Agreement. The parties hereto acknowledge and agree that the representations, warranties, covenants, agreements, and indemnities contained in the Purchase Agreement, as amended by the Implementation Agreement, will not be superseded hereby but will remain in full force and effect to the full extent provided therein. In the event of any conflict between the provisions of this Assignment (including the exhibits) and the provisions of the Purchase Agreement, as amended by the Implementation Agreement, (including the Schedules and

exhibits), the provisions of the Purchase Agreement, as amended by the Implementation Agreement, shall govern, supersede and control in all respects to the extent of such conflict.

5. Governing Law. This Assignment, the negotiation, execution or performance of this Assignment and any disputes arising under or related hereto (whether for breach of contract, tortious conduct, or otherwise) shall be governed and construed in accordance with the Laws of the State of Delaware, without reference to its conflicts of law principles.

6. Entire Agreement. This Assignment, and the exhibits annexed hereto, and the Purchase Agreement, as amended by the Implementation Agreement, and the other agreements, certificates, and other documents contemplated hereby and thereby constitute the entire understanding among the parties hereto with respect to the subject matter hereof and thereof, and supersede all other understandings and negotiations with respect thereto. The parties hereto agree to define their rights, liabilities, and obligations with respect to such understanding and the transactions contemplated hereby exclusively in contract pursuant to the express terms and provisions of this Assignment, and the parties hereto expressly disclaim that they are owed any duties or are entitled to any remedies not expressly set forth in this Assignment or the Purchase Agreement, as amended by the Implementation Agreement.


7. Counterparts. This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when each party hereto shall have received counterparts hereof signed by each of the other parties hereto. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .peg or similar attachment to electronic mail (any such delivery, an “**Electronic Delivery**”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto, each other party hereto shall re-execute the original form of this Assignment and deliver such form to all other parties. No party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties have duly executed this Assignment as of the date first written above.

ASSIGNORS:


AKORN, INC.

By: 

Name: Joseph Bonaccorsi

Title: Executive Vice President, General Counsel and Secretary


ADVANCED VISION RESEARCH, LLC

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory


HI-TECH PHARMACAL CO., LLC

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

AKORN ANIMAL HEALTH, LLC

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

CLOVER PHARMACEUTICALS LLC

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

AKORN INTERNATIONAL S.À.R.L.

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

OAK PHARMACEUTICALS, LLC

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

INSPIRE PHARMACEUTICALS, LLC.

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

VERSAPHARM LLC

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

ASSIGNEE:

AKORN OPERATING COMPANY LLC

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Executive Vice President, General Counsel and Secretary

[SIGNATURE PAGE TO TRADEMARK ASSIGNMENT AGREEMENT]

TRADEMARK
REEL: 007101 FRAME: 0031

EXHIBIT A
Trademark Applications

Title	Country	Application No.	Filing Date	Status	Owner
AKORN	Albania (IR)	1336041	9/12/2016	Pending	Akorn, Inc.
AKORN	South Korea (IR)	1336041	9/12/2016	Pending	Akorn, Inc.
AKORN	Bangladesh	202646	10/2/2016	Pending	Akorn, Inc.
AKORN	Botswana	BW/M/2016/00839	9/27/2016	Pending	Akorn, Inc.
AKORN	China (IR)	1336041	9/12/2016	Pending	Akorn, Inc.
AKORN	Ethiopia	FTM/8414/17	3/1/2017	Pending	Akorn, Inc.
AKORN	Indonesia	D002016047722	10/6/2016	Pending	Akorn, Inc.
AKORN	Kuwait	183751	9/25/2016	Pending	Akorn, Inc.
AKORN	Nigeria	F/TM/O/2016/109648	10/4/2016	Pending	Akorn, Inc.
AKORN	Qatar	110397	11/29/2016	Pending	Akorn, Inc.
AKORN	South Africa	2016/26761	9/19/2016	Pending	Akorn, Inc.
AKORN	Sri Lanka	211594	9/27/2016	Pending	Akorn, Inc.
AKORN	Yemen	77345	12/17/2016	Pending	Akorn, Inc.
STERILID	New Zealand	1131346	10/1/2019	Pending	Advanced Vision Research, Inc.
THEARTEARS	Norway (Int'l Reg.)	1197342	1/21/2014	Pending	Advanced Vision Research, Inc.
THEARTEARS	Singapore (Int'l Reg.)	1197342	1/21/2014	Pending	Advanced Vision Research, Inc.
THEARTEARS	South Africa	2014/01774	1/21/2014	Pending	Advanced Vision Research, Inc.
THEARTEARS	Switzerland (Int'l Reg.)	1197342	1/21/2014	Pending	Advanced Vision Research, Inc.
AKORN	India	3537421	9/12/2016	Pending	Akorn, Inc.
AKORN	Nigeria	F/TM/O/2014/18707	6/18/2014	Pending	Akorn, Inc.
AK-BETAX	Nigeria	F/TM/O/2014/18595	6/16/2014	Pending	Akorn, Inc.
AK-BRIMON	Nigeria	F/TM/O/2014/18626	6/17/2014	Pending	Akorn, Inc.
AK-CMC	Nigeria	F/TM/O/2014/18706	6/18/2014	Pending	Akorn, Inc.
AK-CROMO	Nigeria	F/TM/O/2014/18630	6/17/2014	Pending	Akorn, Inc.
AK-DRAZINE	Nigeria	F/TM/O/2014/18625	6/17/2014	Pending	Akorn, Inc.
AK-KETOR	Nigeria	F/TM/O/2014/18622	6/17/2014	Pending	Akorn, Inc.
AK-LATAN	Nigeria	F/TM/O/2014/18623	6/17/2014	Pending	Akorn, Inc.

Title	Country	Application No.	Filing Date	Status	Owner
AK-MELLO	Nigeria	F/TM/O/2014/18705	6/18/2014	Pending	Akorn Inc.
AK-NAPHALIN	Nigeria	F/TM/O/2014/18704	6/18/2014	Pending	Akorn Inc.
AK-NEO-P	Nigeria	F/TM/O/2014/18592	6/16/2014	Pending	Akorn Inc.
AK-TEARS	Nigeria	F/TM/O/2014/18593	6/16/2014	Pending	Akorn Inc.
AK-TIFEN	Nigeria	F/TM/O/2014/18578	6/16/2014	Pending	Akorn Inc.
AKGENTA	Nigeria	F/TM/O/2014/18703	6/18/2014	Pending	Akorn Inc.
AKORNAPH	Nigeria	F/TM/O/2015/70291	11/23/2015	Pending	Akorn Inc.
AKORNBET	Nigeria	F/TM/O/2015/70285	11/23/2015	Pending	Akorn Inc.
AKORNCROM	Nigeria	F/TM/O/2015/70288	11/23/2015	Pending	Akorn Inc.
AKORNTTEARS	Nigeria	F/TM/O/2015/70292	11/23/2015	Pending	Akorn Inc.
AKORNTENAC	Nigeria	F/TM/O/2015/70293	11/23/2015	Pending	Akorn Inc.
AKORNTMOL	Nigeria	F/TM/O/2015/70286	11/23/2015	Pending	Akorn Inc.
AKORNTIFEN	Nigeria	F/TM/O/2015/70287	11/23/2015	Pending	Akorn Inc.
AKORNTRIX	Nigeria	F/TM/O/2015/70290	11/23/2015	Pending	Akorn Inc.
AKORN ROLAC	Nigeria	F/TM/O/2015/70294	11/23/2015	Pending	Akorn Inc.

Registered Trademarks

Title	Country	Application No.	Registration No.	Owner
ADVANCING THE NEW VISION	USA	85114820	3954229	Akorn, Inc.
AK-FLUOR	USA	73652686	1464246	Akorn, Inc.
AKORN	Algeria	164287	99676	Akorn, Inc.
AKORN	Australia (IR)	1336041	1336041	Akorn, Inc.
AKORN	Bosnia (IR)	1336041	1336041	Akorn, Inc.
AKORN	Canada	1792618	TMA987817	Akorn, Inc.
AKORN	Costa Rica	2016-0009676	261950	Akorn, Inc.
AKORN	EUTM (IR)	1336041	1336041	Akorn, Inc.
AKORN	Guatemala	2016009653	229620	Akorn, Inc.
AKORN	Hong Kong	303911643	303911643	Akorn, Inc.
AKORN	India (IR)	1336041	1336041	Akorn, Inc.
AKORN	Iceland (IR)	1336041	1336041	Akorn, Inc.
AKORN	Israel (IR)	292976	292976	Akorn, Inc.

Title	Country	Application No.	Registration No.	Owner
AKORN	Jordan	149710	149710	Akorn, Inc.
AKORN	Kenya	94117	94117	Akorn, Inc.
AKORN	Kosovo	KS/M/2016/1311	21362	Akorn, Inc.
AKORN	Lebanon	N/A	176515	Akorn, Inc.
AKORN	Macedonia (IR)	1336041	1336041	Akorn, Inc.
AKORN	Malaysia	2016067189	2016067189	Akorn, Inc.
AKORN	Montenegro (IR)	1336041	1336041	Akorn, Inc.
AKORN	Nepal	065274	2016/65274	Akorn, Inc.
AKORN	New Zealand (IR)	1063094	1336041	Akorn, Inc.
AKORN	Norway (IR)	1336041	1336041	Akorn, Inc.
AKORN	Panama	253351-01	253351-01	Akorn, Inc.
AKORN	Russia (IR)	1336041	1336041	Akorn, Inc.
AKORN	Saudi Arabia	1437028411	1437028411	Akorn, Inc.
AKORN	Serbia (IR)	1336041	1336041	Akorn, Inc.
AKORN	Singapore (IR)	1336041	1336041	Akorn, Inc.
AKORN	Switzerland (IR)	1336041	1336041	Akorn, Inc.
AKORN	Taiwan	105056232	01856945	Akorn, Inc.
AKORN	Thailand	160108644	191104966	Akorn, Inc.
AKORN	Turkey (IR)	1336041	1336041	Akorn, Inc.
AKORN	UAE	261898	261898	Akorn, Inc.
AKORN	Ukraine (IR)	1336041	1336041	Akorn, Inc.
AKORN	United Kingdom (IR)	1336041	1336041	Akorn, Inc.
AKORN	Uruguay	441,150	441,150	Akorn, Inc.
AKORN	USA	77589830	3,774,019	Akorn, Inc.
AKORN	USA	86937435	5,076,962	Akorn, Inc.
AKTEN	Israel	291476	291476	Akorn, Inc.
AKTEN	USA	77012922	3,631,872	Akorn, Inc.
AKWA TEARS	USA	75829828	2,429,583	Akorn, Inc.
ALLERGY BUSTER	Canada	1449252	TMA/787366	Hi-Tech Pharmaceutical Company
ALLERGY BUSTER & DESIGN	EU	008506347	008506347	Hi-Tech Pharmaceutical Company
AMICAR	USA	72124870	729,648	Clover Pharmaceuticals Corp (subsidiary of VersalPharm)
ANASED	Canada	0878555	TMA/526130	Akorn Animal Health, Inc.
ANASED	USA	73815445	1,589,685	Akorn Animal Health, Inc.

Title	Country	Application No.	Registration No.	Owner
BETIMOL	International Register	728498 A	728498 A	Akorn International S.A.R.L.
BETIMOL	USA	74628335	1,961,729	Akorn International S.a.r.l
BETIMOL	USA	79128616	4,442,019 (IR No. 728489A)	Akorn International S.a.r.l
BUTORPHIC	USA	77492827	3,648,627	Akorn Animal Health, Inc.
CAPASTAT	Canada	0294218	TMA147966	Akorn, Inc.
CAPASTAT	USA	72221381	808,363	Akorn, Inc.
CHOICE DM	Canada	0821371	TMA535139	Hi-Tech Pharmacal Company
CONTROL THE UNCONTROLLABLE	USA	85961915	4,732,151	Oak Pharmaceuticals
DIABETIC TUSSIN	USA	74389373	1,861,344	Hi-Tech Pharmacal Company
DIADERM	USA	86025876	4,573,615	Hi-Tech Pharmacal Company
EYE RX DIRECT (design)	USA	86773391	5,296,978	Akorn, Inc.
FAST AND FERCE RELIEF	USA	87007235	5,355,854	Hi-Tech Pharmacal Company
AKORN PHARMACAL, INC.	US State/Louisiana	N/A	658495	Hi-Tech Pharmacal Co., Inc.
FLURESS	USA	72203731	789,323	Akorn, Inc.
GENT-AK	USA	73652684	1,464,244	Akorn, Inc.
GROUNDED IN SCIENCE. PROVEN IN PRACTICE	USA	85961910	4,748,523	Oak Pharmaceuticals
HEADACHE BUSTER	Canada	1449250	TMA787365	Hi-Tech Pharmacal Company
IC-GREEN	Canada	0855183	TMA531645	Akorn, Inc.
IC-GREEN	Denmark	V/A 003089 1997	VR 199703234	Akorn, Inc.
IC-GREEN	France	97/684025	97/684025	Akorn, Inc.
IC-GREEN	Germany	39729824.2	39729824	Akorn, Inc.
IC-GREEN	Italy	362017000074996	362017000074996	Akorn, Inc.
IC-GREEN	Switzerland	4701/1997	447511	Akorn, Inc.
IC-GREEN	USA	75315149	2,189,196	Akorn, Inc.
INAPS INE	USA	72190096	783,911	Akorn, Inc.
INDIGO CARMINE	USA	75825569	2,389,845	Akorn, Inc.

Title	Country	Application No.	Registration No.	Owner
HYCLIA	Argentina	3011174	2442900	Inspire Pharmaceuticals, Inc.
INSPIRE	USA	76308782	2,578,523	Inspire Pharmaceuticals, Inc.
INSPIRE AND DESIGN	USA	76309035	2,578,526	Inspire Pharmaceuticals, Inc.
JEFFREY P. GILBARD, MD	USA	85121025	4,556,180	Advanced Vision Research, Inc.
MAGINEX	Canada	1083318	TMA641833	Hi-Tech Pharmacal Company
MAGINEX	USA	76052135	2,541,622	Hi-Tech Pharmacal Company
MAG-OX 400	USA	75576028	2,633,768	Hi-Tech Pharmacal Company
MASTER OF MAGNESIUM	USA	87007233	5,355,853	Hi-Tech Pharmacal Company
MULTI-BETIC	USA	86210334	4,613,666	Hi-Tech Pharmacal Company
MYOCHRYSSINE	USA	76178246	2,509,820	Akorn, Inc.
MYORISAN	Canada	1809727	TMA1031869	VersaPharm Incorporated
myorisan	USA	85071559	4,199,023	VersaPharm Incorporated
NEMBUTAL	Canada	0181445	UCA17215	Oak Pharmaceuticals
NEMBUTAL	USA	71308321	285,003	Oak Pharmaceuticals, Inc.
OSMO-CORRECTION	USA	85967253	4,837,201	Advanced Vision Research, Inc.
PAREMYD	USA	75839701	2,775,998	Akorn, Inc.
PHARMACEUTICAL GRADE (& design)	USA	78329276	3,272,765	Hi-Tech Pharmacal Company
RESTORES EYES NATURAL BALANCE	USA	85967251	4,846,473	Advanced Vision Research, Inc.
SINUS BUSTER	Canada	1378181	TMA733034	Hi-Tech Pharmacal Company
SINUS BUSTER	USA	78862364	3,194,160	Hi-Tech Pharmacal Company
SINUS BUSTER ALL NATURAL NASAL SPRAY	USA	78850704	3,503,088	Hi-Tech Pharmacal Company
SINUS GENIE	Canada	1378171	TMA732672	Hi-Tech Pharmacal Company

Title	Country	Application No.	Registration No.	Owner
STERILID	Australia	1064550	1064550	Advanced Vision Research, Inc.
STERILID	EU	004549721	004549721	Advanced Vision Research, Inc.
STERILID	India	1376561	1376561	Advanced Vision Research, Inc.
STERILID	Mexico	731418	907,931	Advanced Vision Research, Inc.
STERILID	USA	78459733	3,140,041	Advanced Vision Research, Inc.
T TAYLOR PHARMACEUTICALS AN AKORN COMPANY	USA	75572570	2,340,300	Akorn, Inc.
TEARS RENEWED	USA	75829829	2,429,584	Akorn, Inc.
THERA LID	Canada	1387723	TMA766,079	Advanced Vision Research, Inc.
THERA TEARS	EU	002996155	002996155	Advanced Vision Research, Inc.
THERA TEARS	Mexico	731417	902036	Advanced Vision Research, Inc.
THERA TEARS	USA	88457133	5,943,133	Advanced Vision Research, Inc.
THERA TEARS STERILID	USA	78459728	3,181,614	Advanced Vision Research, Inc.
THERA TEARS	USA	74615598	2,041,112	Advanced Vision Research, Inc.
THERAPY FOR YOUR EYES	USA	86260607	4,843,058	Advanced Vision Research, Inc.
THERAREARS EXTRA	USA	87049747	5,586,699	Advanced Vision Research, Inc.
THERATEARS	Australia	730182	730182	Advanced Vision Research, Inc.
THERATEARS	Canada	1085366	TMA573256	Advanced Vision Research, Inc.
THERATEARS	Canada	1153395	TMA641310	Advanced Vision Research, Inc.
THERATEARS	EU	002153476	002153476	Advanced Vision Research, Inc.

Title	Country	Application No.	Registration No.	Owner
THERATEARS	Guatemala	2014000962	201476	Advanced Vision Research, Inc.
THERATEARS	India	1376560	1376560	Advanced Vision Research, Inc.
THERATEARS	International Register	1197342	1197342	Advanced Vision Research, Inc.
THERATEARS	Lebanon	N/A	155229	Advanced Vision Research, Inc.
THERATEARS	New Zealand	274324	274324	Advanced Vision Research, Inc.
THERATEARS	USA	76427523	2,770,188	Advanced Vision Research, Inc.
THERATEARS STERILID	USA	78459728	3,181,614	Advanced Vision Research, Inc.
TOLAZINE	USA	76548343	2,905,937	Akorn Animal Health, Inc.
TYPE YOU	Canada	1728450	TMA1040395	Akorn, Inc.
TYPE YOU	USA	86631044	5,291,486	Akorn, Inc.
TYPE YOU DIABETIC CARE	Canada	1776693	TMA1047727	Akorn, Inc.
TYPE YOU DIABETIC CARE	USA	86966811	5,297,364	Akorn, Inc.
UROMAG	USA	72450878	974,841	Hi-Tech Pharmaceutical Company
MYORISAN	Mexico	1144174	1217500	VersaPharm Incorporated
VERSAPHARM INCORPORATED	USA	76269614	2,588,146	VersaPharm Incorporated
VERSAPHARM INCORPORATED X	USA	76269637	2,685,550	VersaPharm Incorporated
AKORN PHARM, INC.	US State/Louisiana	N/A	658517	VersaPharm Incorporated
VETAKET	USA	74266573	1,803,032	Akorn Animal Health, Inc.
VO SOL	USA	72081126	696,678	Hi-Tech Pharmaceutical Company
YOBINE	USA	73815446	1,587,410	Akorn Animal Health, Inc.
ZOSTRIX	USA	78660833	3,106,587	Hi-Tech Pharmaceutical Company
ZOSTRIX	USA	73576274	1,423,561	Hi-Tech Pharmaceutical Company
THERATEARS	Kuwait	N/A	130439	Advanced Vision Research, Inc.

